인사이트

Insights From Our Experts

Articles

What’s Holding Back AI Adoption? Three Insights from Recent Study

Artificial Intelligence (AI) continues to change at warp speed, creating a “pull” versus “push” customer engagement model where a growing percentage of people ‘pull’ the information they want today from platforms like ChatGPT or Claude, making…

White Paper: The Increasing Role of AI in Improving the Diagnostic Imaging Landscape
The Increasing Role of AI in Improving the Diagnostic Imaging Landscape

Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI…

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs

The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…

Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare

EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and…

Finding the Human Element Amid the Algorithms

The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger?  Spend more than a few minutes of…

Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways

Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by Joey Pecoraro and Christopher Nüesch from EVERSANA MANAGEMENT CONSULTING,…

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA

Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
New Insights into Brain Volume Loss in MS

We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying…

3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks

Are you a pharmaceutical manufacturer looking to navigate the complex world of Integrated Delivery Networks (IDNs)? These powerful entities, which manage multiple healthcare facilities, are key players in delivering high-quality, cost-effective, and patient-centered care. But how…

Digital Innovation and the Direct-To-Patient Model

Innovation is of no worth if it doesn’t provide better outcomes for patients. Indeed, such advancements should hold as centre the amelioration of the overall patient experience. And that’s where digital developments and a Direct-To-Patient (DTP)…